<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03174210</url>
  </required_header>
  <id_info>
    <org_study_id>ActivoxTitration</org_study_id>
    <nct_id>NCT03174210</nct_id>
  </id_info>
  <brief_title>Effects of Supplemental Oxygen Delivered by a Portable Oxygen Concentrator Compared to a Liquid Oxygen Device in COPD</brief_title>
  <official_title>Effects of Supplemental Oxygen Delivered by a Portable Oxygen Concentrator Compared to a Liquid Oxygen Device in Hypoxemic COPD Patients at Rest</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Schön Klinik Berchtesgadener Land</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Schön Klinik Berchtesgadener Land</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effects of supplemental oxygen on blood&#xD;
      oxygenation at rest in Patients with severe to very severe COPD comparing the portable oxygen&#xD;
      concentrator (Activox™ 4L) to a liquid continuous oxygen device (Companion®).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been proven that supplemental oxygen increases oxygen saturation and reduces dyspnea&#xD;
      in hypoxemic COPD Patients. There are different oxygen delivery systems available, some of&#xD;
      them operating with liquid oxygen and others by concentrating the ambient air&#xD;
      (concentrators). An advantage of the concentrator system is, that there is no refill&#xD;
      required, but only a power plug and plug socket, enabling the patient for higher mobility and&#xD;
      to be more autonomous. There are only few publications about whether portable oxygen&#xD;
      concentrators have a comparable efficiency on oxygen saturation to liquid oxygen devices with&#xD;
      continuous flow (LOD) or not. Until now there are no official recommendations about how to&#xD;
      convert the oxygen flow rate for LOD (liter per minute) into the corresponding level of the&#xD;
      POC.&#xD;
&#xD;
      Therefore, we investigate the comparability of the portable oxygen concentrator Activox™ 4L&#xD;
      (POC) to a liquid oxygen device (Companion®) in 30 hypoxemic COPD patients at rest.&#xD;
&#xD;
      As a baseline assessment, the patients will receive a bodyplethysmography, blood gas analysis&#xD;
      without using supplemental oxygen and an evaluation of the diffusion capacity of the lung for&#xD;
      CO.&#xD;
&#xD;
      The study will be conducted on 2 consecutive days. 15 patients will be randomized into two&#xD;
      different groups: First group will start with POC and will continue the following day with&#xD;
      LOD; The second group will start with LOD and continue with POC (cross-over design). All&#xD;
      patients will use the same oxygen devices during the study assessments (LOD: Companion 1000&#xD;
      (CE 0050), Chart Industries Inc., Garfiel Heights, OH, USA; POC: Activox™ 4L, Inovalabs Inc.,&#xD;
      Texas, USA). On both days of the study, patients will be connected to one of the two systems&#xD;
      via nasal cannula for a total time period of 40 minutes, while the patient remains in a&#xD;
      sitting position without talking. The oxygen flow rate starts at 1liter/min (LOD) or Level 1&#xD;
      (POC) and will be increased every 10 minutes to the next higher level until the maximum of&#xD;
      4l/min (LOD) or level 4 (POC) is reached. Blood gases were taken and breathing frequency will&#xD;
      be recorded at the end of each Oxygen Level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2017</start_date>
  <completion_date type="Actual">September 15, 2017</completion_date>
  <primary_completion_date type="Actual">September 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>patients will be randomized into two different Groups (prospective cross-over design)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between LOD and POC in Partial pressure of oxygen levels</measure>
    <time_frame>after 10 minutes of each LOD step compared to 10 minutes of each POC step</time_frame>
    <description>PO2 values between LOD and POC at comparable Levels of oxygen supply (1liter/minute LOD will be compared to Level 1 of POC until 4liters/Minute LOD to Level 4 of POC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference between LOD and POC in Partial pressure of carbon dioxide levels</measure>
    <time_frame>after 10 minutes of each LOD step compared to 10 minutes of each POC step</time_frame>
    <description>PCO2 values between LOD and POC at comparable Levels of oxygen supply (1liter/minute LOD will be compared to Level 1 of POC until 4liters/Minute LOD to Level 4 of POC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of partial pressure of Oxygen from one POC step to the next step</measure>
    <time_frame>after 10 minutes of one POC step compared to after 10 minutes of the next POC step</time_frame>
    <description>Change in PO2 values from e.g. POC step 1 to POC step 2, step 2 to 3 etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of partial pressure of carbon dioxide from one POC step to the next step</measure>
    <time_frame>after 10 minutes of one POC step compared to after 10 minutes of the next POC step</time_frame>
    <description>Change in PCO2 values between e.g. POC step 1 to POC step 2, step 2 to 3 etc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>COPD patients with delivery order 1, 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will use two different Oxygen devices at rest (1.liquid oxygen device (Companion R), 2. portable Oxygen concentrator (Activox TM 4L))</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD patients with delivery order 2,1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will use two different Oxygen devices at rest (1. portable Oxygen concentrator (Activox TM 4L), 2. liquid oxygen device (Companion R))</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>liquid oxygen device (LOD)</intervention_name>
    <description>This oxygen Supplementation is used in special order</description>
    <arm_group_label>COPD patients with delivery order 1, 2</arm_group_label>
    <arm_group_label>COPD patients with delivery order 2,1</arm_group_label>
    <other_name>Companion 1000 Chart Industries, Inc. Garfield Heights, USA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>portable oxygen concentrator (POC)</intervention_name>
    <description>This oxygen Supplementation is used in special order</description>
    <arm_group_label>COPD patients with delivery order 1, 2</arm_group_label>
    <arm_group_label>COPD patients with delivery order 2,1</arm_group_label>
    <other_name>Activox™ 4L, Inovalabs Inc., Texas, USA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COPD patients with hypoxemia at rest (paO2 &lt; 55 or 60 mmHg, according to the recent&#xD;
             supplemental oxygen guidelines [Hadringe, M., et al., British Thoracic Society&#xD;
             guidelines for home oxygen use in adults. Thorax, 2015. 70 Suppl 1: p. i1-43.]&#xD;
&#xD;
          -  Participation in an inpatient pulmonary rehabilitation program (Schön Klinik BGL)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The Need of more than 4 Liter/min Oxygen at rest to achieve PaO2 &gt; 55 or 60mmHg&#xD;
&#xD;
          -  Signs of acute exacerbation&#xD;
&#xD;
          -  General exclusion criteria for exercise tests, e.g. acute coronary syndrome, acute&#xD;
             myo- or pericarditis, acute lung embolism, pulmonary infarction, acute uncontrolled&#xD;
             heart insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Kenn, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schoen Klinik Berchtesgadener Land</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Schoen Klinik Berchtesgadener Land</name>
      <address>
        <city>Schoenau Am Koenigssee</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>May 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2017</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Schön Klinik Berchtesgadener Land</investigator_affiliation>
    <investigator_full_name>Klaus Kenn</investigator_full_name>
    <investigator_title>Prof. Dr. Klaus Kenn</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>supplemental oxygen</keyword>
  <keyword>oxygen concentrator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

